NUVL vs. TEVA, SMMT, GMAB, ASND, VTRS, RDY, QGEN, BBIO, MRNA, and VRNA
Should you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry.
Nuvalent vs. Its Competitors
Nuvalent (NASDAQ:NUVL) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.
97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 10.2% of Nuvalent shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Nuvalent had 1 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 14 mentions for Nuvalent and 13 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.00 beat Nuvalent's score of 0.87 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.
Nuvalent presently has a consensus target price of $120.91, indicating a potential upside of 50.25%. Teva Pharmaceutical Industries has a consensus target price of $24.71, indicating a potential upside of 23.82%. Given Nuvalent's higher possible upside, equities research analysts plainly believe Nuvalent is more favorable than Teva Pharmaceutical Industries.
Nuvalent has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500.
Nuvalent has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.
Nuvalent has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -0.95%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Nuvalent's return on equity.
Summary
Nuvalent beats Teva Pharmaceutical Industries on 9 of the 16 factors compared between the two stocks.
Get Nuvalent News Delivered to You Automatically
Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvalent Competitors List
Related Companies and Tools
This page (NASDAQ:NUVL) was last updated on 9/13/2025 by MarketBeat.com Staff
Free NUVL Stock Alerts